Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.
OBJECTIVE
Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease.


METHODS
We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA.


RESULTS
Concentrations of sRAGE were significantly lower in patients with definite NASH (1080+/-392 pg/mL, P<0.01) and borderline NASH (1050+/-278 pg/mL, P<0.05) compared to controls (1480+/-387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05).


CONCLUSIONS
Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.
Yilmaz
Yusuf
Y
Department of Gastroenterology, Marmara University, School of Medicine, 34662, Altunizade, Istanbul, Turkey. yusufyilmaz@uludag.edu.tr
Ulukaya
Engin
E
Gul
Ozen Oz
OO
Arabul
Mahmut
M
Gul
Cuma Bulent
CB
Atug
Ozlen
O
Oral
Arzu Yilmaztepe
AY
Aker
Sibel
S
Dolar
Enver
E
D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005234:Fatty Liver / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000097:blood*
D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic